Patent US3719158A successfully refreshed from Google Patents.
Patent US1948473A successfully refreshed from Google Patents.
Patent US4278667A successfully refreshed from Google Patents.
US4278667A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating tardive dyskinesia by oral dosage form of a physostigmine compound
Assignee: O'NEAL JONES & FELDMAN Inc A CORP OF DE
•
Filing: 1980-06-02
•
Granted: 1981-07-14
•
Expires: 2000-06-02
Abstract
Abstract This invention relates to the use of a physostigmine compound in oral dosage form for the relief, cure or remission of tardive dyskinesia in living animal bodies. The physostigmine compounds include physostigmine, the salts of physostigmine and the esters of physostigmine. The oral dosage form may be in the form of tablets, coated or uncoated, capsules, liquids, powders and any other form of oral dosage which can be ingested into the living animal body. Physostigmine is also known as eserine.
Inventors
- 👤 James B. Madison
- 👤 Larry K. Hiland
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 09:22
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/60; A61K31/625
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
59 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body in oral dosage form a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate at intervals of time not less than about four hours apart in an amount effective to relieve the tardive dyskinesia.
Claim 2
Independent Claim
59 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body in oral dosage form a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate at intervals of time not less than about four hours apart in an amount effective to relieve the tardive dyskinesia.
Claim 3
Dependent Claim
18 words
The method according to claim 1 wherein said oral dosage form is in the form of a tablet.
Claim 4
Dependent Claim
18 words
The method according to claim 1 wherein said oral dosage form is in the form of a liquid.
Claim 5
Dependent Claim
18 words
The method according to claim 1 wherein said oral dosage form is in the form of a capsule.
Claim 6
Dependent Claim
18 words
The method according to claim 1 wherein said oral dosage form is in the form of a powder.
Claim 7
Dependent Claim
22 words
The method according to claim 1 wherein said physostigmine compound is in the form of enteric coated particles adapted for timed release.
Claim 8
Dependent Claim
32 words
The method according to claim 1 wherein said physostigmine compound is ingested into said living animal body in an amount of 0.000002 to 0.000064 percent by weight of said living animal body.
Claim 9
Independent Claim
68 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body in oral dosage form from about 5.0 to about 20.0 milligrams daily of a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate at intervals of time not less than about four hours apart in incremental amounts effective to relieve the tardive dyskinesia.
Claim 10
Independent Claim
68 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body in oral dosage form from about 5.0 to about 20.0 milligrams daily of a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate at intervals of time not less than about four hours apart in incremental amounts effective to relieve the tardive dyskinesia.
Claim 11
Independent Claim
49 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body on a three times per day time schedule about 15 to 20 milligrams total of physostigmine salicylate in the form of tablets containing about one milligram each of active physostigmine salicylate.
Claim 12
Independent Claim
49 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body on a three times per day time schedule about 15 to 20 milligrams total of physostigmine salicylate in the form of tablets containing about one milligram each of active physostigmine salicylate.
Claim 13
Independent Claim
57 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body at intervals of time not less than about four hours apart an oral dosage containing about 0.5 to about 32.0 milligrams of a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate.
Claim 14
Independent Claim
57 words
A method of treating tardive dyskinesia in a living animal body comprising ingesting into said living animal body at intervals of time not less than about four hours apart an oral dosage containing about 0.5 to about 32.0 milligrams of a physostigmine compound selected from the group consisting of physostigmine, physostigmine salicylate, physostigmine sulfite and physostigmine sulfate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-07-13 | 1985-01-12 | 1985-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-07-13 | 1989-01-12 | 1989-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-07-13 | 1993-01-12 | 1993-07-14 | $7700.00 | Window Closed / Lapsed |